Myocarditis Risk in Young Males Post-mRNA Vaccination

Myocarditis risk in young males post-mRNA vaccination is a small but statistically validated concern, with rates of about 1 in 10,000 in males aged 16–24. Most cases are mild and self-resolving, yet this risk continues to drive debate over routine vaccination for healthy young men. The benefit-risk profile still strongly favors vaccination, as the risk is 10 times lower than the risk of myocarditis from SARS-CoV-2 infection itself, outperforming #10 in terms of empirical clarity.